Combination therapy of allergic rhinitis
DOI: 10.32364/2587-6821-2025-9-2-3
I.V. Demko1,2, E.A. Sobko1,2, A.Yu. Kraposhina1,2, V.A. Chernykh1,2
1Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation
2Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation
Aim: to evaluate the efficacy of a fixed-dose combination of mometasone furoate and olopatadine hydrochloride in patients with seasonal allergic rhinitis (AR), using data from individuals treated at a pulmonary allergy center.
Materials and Methods: the efficacy of a combined intranasal formulation of mometasone furoate and olopatadine hydrochloride was evaluated in adult patients with moderate-to-severe seasonal AR in a real clinical practice at the pulmonary allergy center. A total of 30 patients were included in the study. Participants received the fixed-dose combination of mometasone furoate (25 µg) and olopatadine hydrochloride (600 µg) at a dosage of two sprays per nostril twice daily for 14 days. Symptom severity of AR and associated conjunctivitis was assessed at baseline, as well as after 7 and 14 days of treatment, using standardized tools including the Total Nasal Symptom Score (TNSS), Visual Analog Scale (VAS), Total Ocular Symptom Score (TOSS), and Sino-Nasal Outcome Test 22 (SNOT-22).
Results: at baseline, all patients reported nasal congestion, rhinorrhea, nasal itching or burning, and sneezing. Additionally, 15 patients (50%) presented with concomitant allergic conjunctivitis. Following the therapy initiation, there was a statistically significant reduction in TNSS, VAS, TOSS, and SNOT-22 scores at both the 7-day and 14-day evaluations (p <0.0001 for all comparisons relative to baseline). Symptom relief was noted as early as the first day of treatment in 17 patients (56.6%), with substantial clinical improvement observed by day 7. By day 14, 80% of patients with concomitant conjunctivitis experienced complete resolution of symptoms.
Conclusion: the fixed-dose combination of mometasone furoate and olopatadine hydrochloride demonstrated high efficacy in the management of seasonal AR, achieving substantial symptom control. Importantly, the treatment also provided effective management of concomitant allergic conjunctivitis, significantly enhancing patients' quality of life.
Keywords: seasonal rhinitis, allergic rhinitis, nasal symptoms, intranasal glucocorticosteroids, fixed combination, olopatadine hydrochloride, mometasone furoate.
For citation: Demko I.V., Sobko E.A., Kraposhina A.Yu., Chernykh V.A. Combination therapy of allergic rhinitis. Russian Medical Inquiry. 2025;9(2):112–118 (in Russ.). DOI: 10.32364/2587-6821-2025-9-2-3
About the authors:
Irina V. Demko — Dr. Sc. (Med.), Professor, Head of the Department of Hospital Therapy and Immunology with Postgraduate Education course, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; Head of the Pulmonary and Allergy Center, Krasnoyarsk Regional Clinical Hospital; 3A, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0000-0001-8982-5292
Elena A. Sobko — Dr. Sc. (Med.), Professor of Department of Hospital Therapy and Immunology with Postgraduate Education course, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; Head of the Department of Allergology, Krasnoyarsk Regional Clinical Hospital; 3A, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0000-0002-9377-5213
Angelina Yu. Kraposhina — C. Sc. (Med.), Associate Professor of the Department of Hospital Therapy and Immunology with Postgraduate Education course, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; pulmonologist, Krasnoyarsk Regional Clinical Hospital; 3A, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0000-0002-0586-8349
Victoria A. Chernykh — Assistant Professor of the Department of Hospital Therapy and Immunology with Postgraduate Education course, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; allergologist-immunologist, Krasnoyarsk Regional Clinical Hospital; 3A, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0009-0003-9191-5475
Contact information: Elena A. Sobko, e-mail: sobko29@mail.ru
Financial Disclosure: the article was prepared with the financial support of the Glenmark company.
There is no conflict of interest.
Received 10.01.2025.
Revised 04.02.2025.
Accepted 27.02.2025.
2. Астафьева Н.Г., Баранов А.А., Вишнева Е.А. и др. Аллергический ринит: клинические рекомендации. М.; 2020.Astafieva N.G., Baranov A.A., Vishneva E.A. et al. Allergic rhinitis: clinical guidelines. M.; 2020 (in Russ.).
3. Российская ассоциация аллергологов и клинических иммунологов. Федеральные клинические рекомендации по аллергическому риниту. М.; 2024.Russian Association of Allergologists and Clinical Immunologists. Federal clinical guidelines for allergic rhinitis. M.; 2024 (in Russ.).
4. Canonica G.W., Bousquet J., Mullol J. et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 85):17–25. DOI: 10.1111/j.1398-9995.2007.01549.x
5. Ненашева Н.М., Шиленкова В.В. Контроль симптомов аллергического ринита у взрослых лиц в Российской Федерации: результаты онлайн-опроса. РМЖ. Медицинское обозрение. 2021;5(1):25–31. DOI: 10.32364/2587-6821-2021-5-1-25-31Nenasheva N.M., Shilenkova V.V. Control of allergic rhinitis symptoms in adults in the Russian Federation: online survey results. Russian Medical Inquiry. 2021;5(1):25–31 (in Russ.). DOI: 10.32364/2587-6821-2021-5-1-25-31
6. Demoly P., Bousquet P.J., Mesbah K. et al. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy. 2013;43(8):881–888. DOI: 10.1111/cea.12121
7. Bernstein J.A. Allergic and mixed rhinitis: Epidemiology and natural history. Allergy Asthma Proc. 2010;31(5):365–369. DOI: 10.2500/aap.2010.31.3380
8. Maurer M., Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy. 2007;62(9):1057–1063. DOI: 10.1111/j.1398-9995.2007.01367.x
9. Cardell L.O., Olsson P., Andersson M. et al. TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26:15082. DOI: 10.1038/npjpcrm.2015.82
10. Jutel M., Agache I., Bonini S. et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556–568. DOI: 10.1016/j.jaci.2015.04.047
11. Caimmi D., Baiz N., Sanyal S. et al. Discriminating severe seasonal allergic rhinitis. Results from a large nation-wide database. PLoS One. 2018;13(11):e0207290. DOI: 10.1371/journal.pone.0207290
12. Bousquet J., Meltzer E.O., Couroux P. et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726–1732.e6. DOI: 10.1016/j.jaip.2018.01.031
13. Passali D., Spinosi M.C., Crisanti A., Bellussi L.M. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016;11:18. DOI: 10.1186/s40248-016-0054-3
14. Du K., Qing H., Zheng M. et al. Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. Ann Allergy Asthma Immunol. 2020;125(5):589–596.e3. DOI: 10.1016/j.anai.2020.06.038
15. Zitt M., Kosoglou T., Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007;30(4):317–326. DOI: 10.2165/00002018-200730040-00004
16. Hampel F.C., Pedinoff A.J., Jacobs R.L. et al. Olopatadine mometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019;40(4):261–272. DOI: 10.2500/aap.2019.40.4223
17. Bousquet J., Anto J.M., Bachert C. et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6:95. DOI: 10.1038/s 41572-020-00227-0
18. Bousquet J., Schünemann H.J., Togias A. et al. Next-generation Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. DOI: 10.1016/j. jaci.2019.06.049
19. Patel P., Salapatek A.M., Talluri R.S., Tantry S.K. Pharmacokinetics of intranasal mometasone in the fixed dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Allergy Asthma Proc. 2018;39:232–239. DOI: 10.2500/aap.2018.39.4134
20. Patel P., Salapatek A.M., Talluri R.S., Tantry S.K. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Allergy Asthma Proc. 2018;39:224–231. DOI: 10.2500/aap.2018.39.4133
21. Andrews С.P., Mohar D., Salhi Y., Tantry S.K. Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2020;124:171–178. DOI: 10.1016/j.anai.2019.11.007
22. Gross G.N., Berman G., Amar N.J. et al. Efficacy and safety of olopatadine mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2019;122:630–638. DOI: 10.1016/j.anai.2019.03.017
23. Patel P., Salapatek A.M., Tantry S.K. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol. 2019;122(2):160–166. DOI: 10.1016/j.anai.2018.10.011
24. Segall N., Prenner B., Lumry W. et al. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2019;40(5):301–310. DOI: 10.2500/aap.2019.40.4233
25. Ненашева Н.М., Назарова Е.В., Терехова Е.П. и др. Эффективность и безопасность комбинированного препарата GSP 301НС у пациентов с САР: результаты российского многоцентрового рандомизированного открытого клинического исследования. Практическая аллергология. 2021;1:66–77. DOI: 10.46393/2712-9667_2021_1_66-77Nenasheva N.M., Nazarova E.V., Terekhova E.P. et al. Efficacy and safety of combined GSP 301NS in patients with SAD: results of a Russian multicenter, randomized, open-label clinical trial. Practical allergology. 2021;1:66–77 (in Russ.). DOI: 10.46393/2712-9667_2021_1_66-77
26. Астафьева Н.Г., Баранов А.А., Вишнева Е.А. и др. Аллергический ринит. Российский аллергологический журнал. 2022;19(1):100–141. DOI: 10.36691/RJA1524Astafieva N.G., Baranov A.A., Vishneva E.A. et al. Allergic rhinitis. Russian Journal of Allergy. 2022;19(1):100–141 (in Russ.). DOI: 10.36691/RJA1524
27. Wise S.K., Lin S.Y., Toskala E. et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. DOI: 10.1002/alr.22073
28. Ayyappanavar S., Sridhar S., Kumar K. et al. Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. Indian J Ophthalmol. 2021;69:257–261. DOI: 10.4103/ijo.IJO_2083_20
29. Husain Q., Hoehle L., Phillips K. et al. The 22-Item Sinonasal Outcome Test as a Tool for the Assessment of Quality of Life and Symptom Control in Allergic Rhinitis. Am J Rhinol Allergy. 2020;34(2):209–216. DOI: 10.1177/1945892419884789
30. Baiardini I., Novakova S., Mihaicuta S. et al. Adherence to treatment in allergic respiratory diseases. Expert Rev Respir Med. 2019;13(1):53–62. DOI: 10.1080/17476348.2019.1554438
31. Baroody F.M., Naclerio R.M. Nasal-ocular reflexes and their role in the management of allergic rhinoconjunctivitis with intranasal steroids. World Allergy Organ J. 2011;4(Suppl. 1):S1–5. DOI: 10.1097/ WOX.0b013e3181f32dcd
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать